Becton, Dickinson and Company
NYQ: BDXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Becton, Dickinson and Company's price action across multiple timeframes using regression channels and statistical scoring.
Get BDX Z-Score →About Becton, Dickinson and Company
Healthcare
Medical Instruments & Supplies
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
📊 Fundamental Analysis
Becton, Dickinson and Company demonstrates a profit margin of 8.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 1.6% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is 7.0%, which suggests room for improvement in capital utilization.
At a current price of $154.22, BDX currently sits at the 45th percentile of its 52-week range (Range: $127.59 - $187.35).
💰 Valuation Insight
BDX is valued broadly in line with the sector at a PE of 25.20. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$55.87B
Trailing P/E
25.20
Forward P/E
11.42
Beta (5Y)
0.35
52W High
$187.35
52W Low
$127.59
Avg Volume
2.82M
Day High
Day Low